Novartis prevails in Gilenya patent challenge brought by Teva and Apotex

The U.S. Patent and Trademark Office’s Patent Trial and Appeal Board wrote that petitioners Apotex, Teva (TEVA) and Sun Pharmaceutical failed to show, by a preponderance of the evidence, that claims 1-6 of U.S. Patent No. US 9,187,405 held by Novartis (NVS) related to its Gilenya are unpatentable, according to a decision dated July 11 that was posted to the USPTO site.

https://bit.ly/2uhsiMp